Trikafta/Kaftrio (elexacaftor/tezacaftor/ivacaftor) Disease area(s): Respiratory/rare disease Manufacturer(s): Vertex Pharmaceuticals Incorporated 2024 Sales (USD): $10.24 billion Why it sold so well: Trikafta (marketed as Kaftrio outside the US), a combination therapy of elexacaftor, tezacaftor and ivacaftor, was the primary driver of Vertex Pharmaceuticals strong commercial performance in 2024
Improved Metabolic Health: GLP-1 enhances insulin sensitivity, supporting better blood sugar regulation and contributing to overall metabolic balance
[iii] Johansen PB, Nowak J, Skjaerbaek C, Flyvbjerg A, Andreassen TT, Wilken M, Orskov H
Your personalized plan will be determined during your consultation
If you have any problems, they tell you to email, but after taking your money, they vanish and never answer